These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 2991094

  • 1. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
    Schumm F, Gaertner HJ, Wiatr G, Dichgans J.
    Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
    [Abstract] [Full Text] [Related]

  • 2. [Therapy of myasthenia gravis with cholinesterase inhibitors--principles and pharmacologic monitoring].
    Henze T.
    Fortschr Neurol Psychiatr; 1996 Mar; 64(3):110-21. PubMed ID: 8900891
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
    Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F.
    Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
    Milner-Brown HS, Mellenthin M, Sharma ML, Miller RG.
    Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacokinetics of cholinesterase inhibitors.
    Aquilonius SM, Hartvig P.
    Clin Pharmacokinet; 1986 May; 11(3):236-49. PubMed ID: 3524957
    [Abstract] [Full Text] [Related]

  • 12. Plasma pyridostigmine levels in myasthenia gravis.
    White MC, De Silva P, Havard CW.
    Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
    [Abstract] [Full Text] [Related]

  • 13. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
    Breyer-Pfaff U, Schmezer A, Maier U, Brinkmann A, Schumm F.
    J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
    [Abstract] [Full Text] [Related]

  • 14. The role of anti-acetylcholine receptor antibody in neonatal myasthenia gravis.
    Skoglund RR, Roberts CC, Huddlestone J.
    Bull Los Angeles Neurol Soc; 1978 Jun; 43(2-4):66-9. PubMed ID: 757366
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Changes in the pattern reversal visual evoked potentials in myasthenia gravis.
    Fotiou F, Papakostopoulos D, Hamlatzis P.
    Electromyogr Clin Neurophysiol; 1994 Jun; 34(3):171-5. PubMed ID: 8045249
    [Abstract] [Full Text] [Related]

  • 17. Malabsorption of pyridostigmine in patients with myasthenia gravis.
    Cohan SL, Dretchen KL, Neal A.
    Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.